Fibrogen Stock Performance
| FGEN Stock | USD 7.65 0.42 5.20% |
On a scale of 0 to 100, FibroGen holds a performance score of 2. The firm shows a Beta (market volatility) of 1.84, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, FibroGen will likely underperform. Please check FibroGen's potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to make a quick decision on whether FibroGen's price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in FibroGen are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, FibroGen may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Actual Historical Performance (%)
One Day Return (5.20) | Five Day Return 4.51 | Year To Date Return (42.18) | Ten Year Return (98.76) | All Time Return (98.61) |
Last Split Factor 1:25 | Last Split Date 2025-06-17 |
1 | AstraZenecas Q1 2025 Financial Results | 04/29/2025 |
2 | FibroGen outlines 185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline | 05/13/2025 |
3 | Insider Trading | 06/04/2025 |
4 | FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors FGEN Stock News | 06/09/2025 |
5 | FibroGen Announces 1-for-25 Reverse Stock Split FGEN Stock News | 06/12/2025 |
6 | Adobe, FibroGen And Other Big Stocks Moving Lower In Fridays Pre-Market Session | 06/13/2025 |
7 | FibroGen Trading Down 6.7 percent Whats Next | 06/17/2025 |
8 | Acquisition by Schoeneck James A of 23567 shares of FibroGen at 5.07 subject to Rule 16b-3 | 06/30/2025 |
9 | Acquisition by Juan Graham of 220000 shares of FibroGen at 1.21 subject to Rule 16b-3 | 07/18/2025 |
| Begin Period Cash Flow | 113.7 M | |
| Total Cashflows From Investing Activities | 126 M |
FibroGen Relative Risk vs. Return Landscape
If you would invest 749.00 in FibroGen on April 22, 2025 and sell it today you would earn a total of 16.00 from holding FibroGen or generate 2.14% return on investment over 90 days. FibroGen is currently generating 0.1962% in daily expected returns and assumes 5.7583% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than FibroGen, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
FibroGen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for FibroGen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as FibroGen, and traders can use it to determine the average amount a FibroGen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0341
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | FGEN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.76 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.2 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average FibroGen is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of FibroGen by adding it to a well-diversified portfolio.
FibroGen Fundamentals Growth
FibroGen Stock prices reflect investors' perceptions of the future prospects and financial health of FibroGen, and FibroGen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FibroGen Stock performance.
| Return On Equity | -10.16 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.43) % | ||||
| Operating Margin | (5.40) % | ||||
| Current Valuation | 70.73 M | ||||
| Shares Outstanding | 4.04 M | ||||
| Price To Earning | 97.67 X | ||||
| Price To Book | 53.83 X | ||||
| Price To Sales | 4.42 X | ||||
| Revenue | 29.62 M | ||||
| Gross Profit | (55.85 M) | ||||
| EBITDA | (142.43 M) | ||||
| Net Income | (47.58 M) | ||||
| Cash And Equivalents | 438.13 M | ||||
| Cash Per Share | 4.67 X | ||||
| Total Debt | 73.09 M | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 2.17 X | ||||
| Book Value Per Share | (53.66) X | ||||
| Cash Flow From Operations | (138 M) | ||||
| Earnings Per Share | (30.00) X | ||||
| Market Capitalization | 30.92 M | ||||
| Total Asset | 214.53 M | ||||
| Retained Earnings | (1.89 B) | ||||
| Working Capital | 63.2 M | ||||
| Current Asset | 200.56 M | ||||
| Current Liabilities | 67.18 M | ||||
About FibroGen Performance
By examining FibroGen's fundamental ratios, stakeholders can obtain critical insights into FibroGen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that FibroGen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 74.00 | 70.30 | |
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (1.85) | (1.76) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | 0.26 | 0.25 |
Things to note about FibroGen performance evaluation
Checking the ongoing alerts about FibroGen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for FibroGen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| FibroGen had very high historical volatility over the last 90 days | |
| FibroGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 29.62 M. Net Loss for the year was (47.58 M) with loss before overhead, payroll, taxes, and interest of (55.85 M). | |
| FibroGen currently holds about 438.13 M in cash with (138 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67. | |
| FibroGen has a frail financial position based on the latest SEC disclosures |
- Analyzing FibroGen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether FibroGen's stock is overvalued or undervalued compared to its peers.
- Examining FibroGen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating FibroGen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of FibroGen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of FibroGen's stock. These opinions can provide insight into FibroGen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (30.00) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.